When-to-start-treatment controversy

POZ: START Wars - by Tim Horn: "Few experts and activists argue that the research supporting early treatment is anything less than encouraging. Where there is less agreement, however, is whether enough sound, scientific research has been conducted to spell out the benefits and risks—the increased (or decreased) likelihood of short- and long-term side effects, adherence challenges and the development of drug resistance, for example—of early treatment and to warrant major changes to public policy. In fact, some of the most experienced and trusted sources of HIV prevention and treatment policy are struggling to make the right call."

Note: For more information on the START trial (Strategic Timing of AntiRetroviral Therapy) see http://insight.ccbr.umn.edu/start/